M L Becker1, W P J Franken2, F Karapinar3, R Verzijl-Zeegers4, T Schalekamp5, R T M van der Hoeven6. 1. Pharmacy Foundation of Haarlem Hospitals, Boerhaavelaan 24, 2035 RC, Haarlem, The Netherlands. mbecker@sahz.nl. 2. ATAL-MEDIAL Diagnostics Centers, Hoofddorp, The Netherlands. 3. Sint Lucas Andreas Hospital, Amsterdam, The Netherlands. 4. Amphia Hospital, Breda, The Netherlands. 5. Universiteit Utrecht, Utrecht, The Netherlands. 6. Pharmacy Foundation of Haarlem Hospitals, Boerhaavelaan 24, 2035 RC, Haarlem, The Netherlands.
Abstract
PURPOSE: It is established that omeprazole increases (R)+ warfarin levels with around 10 %. Whether (es)omeprazole also increase the plasma levels of acenocoumarol or phenprocoumon is still uncertain. We analyzed whether addition of (es)omeprazole to acenocoumarol or phenprocoumon increases the international normalized ratio (INR) levels and the risk of overanticoagulation. METHODS: We analyzed all hospital admissions in four teaching hospitals. Patients who used coumarins and pantoprazole or (es)omeprazole simultaneously for at least four consecutive days were included in the study. We analyzed the highest INR level and whether patients had an INR level above six. We compared patients using omeprazole or esomeprazole with patients using pantoprazole, because for pantoprazole, no interaction has been reported. RESULTS: We analyzed 5747 admissions with 4540 patients using one of the drug combinations. For acenocoumarol (4578 admissions), no significant differences were found between users of esomeprazole, omeprazole, and pantoprazole. For phenprocoumon (1169 admissions), the highest INR measured was significantly higher in users of esomeprazole than in users of pantoprazole (4.7 versus 4.3; p = 0.035). No significant difference was found with omeprazole versus pantoprazole (4.3 versus 4.3; p = 0.66). A non-significant association was found between the esomeprazole dose and the highest INR level (p = 0.055). The risk of an INR above six did not differ significantly between esomeprazole and pantoprazole (27.7 % versus 22.9 %; p = 0.34). CONCLUSIONS: The use of esomeprazole simultaneously with phenprocoumon during hospital admissions might increase the anticoagulant effect. The clinical relevance seems to be limited, because no statistically significant increased risk of overanticoagulation was found.
PURPOSE: It is established that omeprazole increases (R)+ warfarin levels with around 10 %. Whether (es)omeprazole also increase the plasma levels of acenocoumarol or phenprocoumon is still uncertain. We analyzed whether addition of (es)omeprazole to acenocoumarol or phenprocoumon increases the international normalized ratio (INR) levels and the risk of overanticoagulation. METHODS: We analyzed all hospital admissions in four teaching hospitals. Patients who used coumarins and pantoprazole or (es)omeprazole simultaneously for at least four consecutive days were included in the study. We analyzed the highest INR level and whether patients had an INR level above six. We compared patients using omeprazole or esomeprazole with patients using pantoprazole, because for pantoprazole, no interaction has been reported. RESULTS: We analyzed 5747 admissions with 4540 patients using one of the drug combinations. For acenocoumarol (4578 admissions), no significant differences were found between users of esomeprazole, omeprazole, and pantoprazole. For phenprocoumon (1169 admissions), the highest INR measured was significantly higher in users of esomeprazole than in users of pantoprazole (4.7 versus 4.3; p = 0.035). No significant difference was found with omeprazole versus pantoprazole (4.3 versus 4.3; p = 0.66). A non-significant association was found between the esomeprazole dose and the highest INR level (p = 0.055). The risk of an INR above six did not differ significantly between esomeprazole and pantoprazole (27.7 % versus 22.9 %; p = 0.34). CONCLUSIONS: The use of esomeprazole simultaneously with phenprocoumon during hospital admissions might increase the anticoagulant effect. The clinical relevance seems to be limited, because no statistically significant increased risk of overanticoagulation was found.
Entities:
Keywords:
Coumarins; Cytochrome P450; Drug interactions; International normalized ratio; Proton-pump inhibitors
Authors: Talitha I Verhoef; Miranda J L Zuurhout; Rianne M F van Schie; William K Redekop; Felix J M van der Meer; Saskia le Cessie; Tom Schalekamp; Anthonius de Boer; Anke Hilse Maitland-van der Zee Journal: Br J Clin Pharmacol Date: 2012-12 Impact factor: 4.335
Authors: Martina Teichert; Charlotte van Noord; Andrė G Uitterlinden; Albert Hofman; Peter N Buhre; Peter A G M De Smet; Sabine Straus; Bruno H Ch Stricker; Loes E Visser Journal: Br J Haematol Date: 2011-03-21 Impact factor: 6.998
Authors: Loes E Visser; Fernie J A Penning-van Bees; A A Harrie Kasbergen; Peter A G M De Smet; Arnold G Vulto; Albert Hofman; Bruno H Ch Stricker Journal: Thromb Haemost Date: 2002-11 Impact factor: 5.249
Authors: S C Cannegieter; F R Rosendaal; A R Wintzen; F J van der Meer; J P Vandenbroucke; E Briët Journal: N Engl J Med Date: 1995-07-06 Impact factor: 91.245